Importantly, GPC3 has been reported to discriminate between HCC and non-malignant lesions (Zhu et al., 2001; Wang et al., 2008) or other liver-associated cancers like cholangiocarcinoma (CCA) (Man et al., 2005). This evidence concerns the gene GPC3 and cholangiocarcinoma.